APA (7th ed.) Citation

Posner, A., Rosenberg, C., Esselen, K. M., Kelly, A., & Bockorny, B. (2026). Acquired TSC1 Mutation as a Mechanism of Alectinib Resistance in ALK -Fused Leiomyosarcoma: Response to Combined ALK and Mammalian Target of Rapamycin Inhibition. JCO Precision Oncology, 10, 1. https://doi.org/10.1200/PO-26-00046

Chicago Style (17th ed.) Citation

Posner, Alisa, Carol Rosenberg, Katharine M. Esselen, Andrew Kelly, and Bruno Bockorny. "Acquired TSC1 Mutation as a Mechanism of Alectinib Resistance in ALK -Fused Leiomyosarcoma: Response to Combined ALK and Mammalian Target of Rapamycin Inhibition." JCO Precision Oncology 10 (2026): 1. https://doi.org/10.1200/PO-26-00046.

MLA (9th ed.) Citation

Posner, Alisa, et al. "Acquired TSC1 Mutation as a Mechanism of Alectinib Resistance in ALK -Fused Leiomyosarcoma: Response to Combined ALK and Mammalian Target of Rapamycin Inhibition." JCO Precision Oncology, vol. 10, 2026, p. 1, https://doi.org/10.1200/PO-26-00046.